JPS59222424A - 神経障害疾患治療剤 - Google Patents

神経障害疾患治療剤

Info

Publication number
JPS59222424A
JPS59222424A JP58095683A JP9568383A JPS59222424A JP S59222424 A JPS59222424 A JP S59222424A JP 58095683 A JP58095683 A JP 58095683A JP 9568383 A JP9568383 A JP 9568383A JP S59222424 A JPS59222424 A JP S59222424A
Authority
JP
Japan
Prior art keywords
gq1b
nervous system
drug
days
gd1b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58095683A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0456010B2 (enExample
Inventor
Katsutaka Nagai
永井　克孝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP58095683A priority Critical patent/JPS59222424A/ja
Publication of JPS59222424A publication Critical patent/JPS59222424A/ja
Publication of JPH0456010B2 publication Critical patent/JPH0456010B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP58095683A 1983-06-01 1983-06-01 神経障害疾患治療剤 Granted JPS59222424A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58095683A JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58095683A JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Publications (2)

Publication Number Publication Date
JPS59222424A true JPS59222424A (ja) 1984-12-14
JPH0456010B2 JPH0456010B2 (enExample) 1992-09-07

Family

ID=14144289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58095683A Granted JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Country Status (1)

Country Link
JP (1) JPS59222424A (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727864A1 (fr) * 1994-12-12 1996-06-14 Synthelabo Utilisation des ligands des sites de liaison peripherique pour les benzodiazepines pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques
WO2001039804A3 (de) * 1999-12-06 2002-04-11 Knoll Ag Gd3-synthase-inhibitoren zur behandlung neuropathologischer störungen
CN103040976A (zh) * 2012-12-31 2013-04-17 陈淑香 一种促进面神经损伤外科吻合术后康复的药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5234912A (en) * 1975-08-13 1977-03-17 Fidia Spa Extraction of ganglioside and application of same to new medicines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5234912A (en) * 1975-08-13 1977-03-17 Fidia Spa Extraction of ganglioside and application of same to new medicines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727864A1 (fr) * 1994-12-12 1996-06-14 Synthelabo Utilisation des ligands des sites de liaison peripherique pour les benzodiazepines pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques
EP0719557A1 (fr) * 1994-12-12 1996-07-03 Synthelabo Utilisation de dérivés d'imidazopyridines pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques
WO2001039804A3 (de) * 1999-12-06 2002-04-11 Knoll Ag Gd3-synthase-inhibitoren zur behandlung neuropathologischer störungen
CN103040976A (zh) * 2012-12-31 2013-04-17 陈淑香 一种促进面神经损伤外科吻合术后康复的药物

Also Published As

Publication number Publication date
JPH0456010B2 (enExample) 1992-09-07

Similar Documents

Publication Publication Date Title
JP3714683B2 (ja) 抗リウマチ剤
Bonadonna et al. Clinical evaluation of adriamycin, a new antitumour antibiotic
CN101010086B (zh) 作为免疫和自身免疫调节剂的神经酰胺衍生物
AU2004242091B2 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
DE69332357T2 (de) Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie
Di Patre et al. Interaction between nerve growth factor and GM1 monosialoganglioside in preventing cortical choline acetyltransferase and high affinity choline uptake decrease after lesion of the nucleus basalis
Karzel et al. Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycane metabolism of fibroblast cultures
US20090041733A1 (en) Methods for cell mobilization using in vivo treatment with hyaluronan (ha)
KR20060063788A (ko) 올리고 핵산 담지 복합체, 이 복합체를 함유하는 의약조성물
CN1794999B (zh) 神经损伤治疗剂
JPS6130521A (ja) 末梢神経障害の疼痛治療用ガングリオシド混合物
EP3964219A1 (en) Pharmaceutical composition for treating sepsis or systemic inflammatory response syndrome, comprising isolated mitochondria as active ingredient
US5183807A (en) Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
Mizushima et al. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats
JPS59222424A (ja) 神経障害疾患治療剤
PT100756B (pt) Novos derivados de gangliosidos, processo para a sua preparacao e composicoes farmaceuticas que os contem
Talmadge et al. Inhibited growth of a reticulum cell sarcoma (M5076) induced in vitro and in vivo by macrophage-activating agents
JPH09227386A (ja) ストレス蛋白質発現増強剤
Nigam Effect of core lipopolysaccharides from Salmonella minnesota R mutants on the survival times of mice bearing Ehrlich tumor
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
US6436911B1 (en) IL-12 production inhibitor
JP4676049B2 (ja) Ｉｌ−１２産生抑制剤
US5916884A (en) Compositions containing a mixture of phosphorus compounds and alkylglycerols
RU2039564C1 (ru) Способ получения препарата натриевой соли днк
RU2812805C1 (ru) Способ ингибирования сигнального пути PD-1/PD-L1 в раковых клетках мочевого пузыря